Sign In
Buy XFOR
$4.04
-0.0700 (-1.70%)
At Close: Jun 02, 2026
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
11:15am, Thursday, 12'th May 2022 Zacks Investment Research
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
10:05am, Thursday, 12'th May 2022 GlobeNewswire Inc.
Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
08:17am, Thursday, 12'th May 2022
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
10:05am, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wit
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
06:05am, Tuesday, 03'rd May 2022
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients wi
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
05:05pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wi
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
01:05pm, Friday, 08'th Apr 2022
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with
X4 Pharmaceuticals to Present at April Investor Conferences
12:05pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people w
X4 Pharmaceuticals to Present at April Investor Conferences
08:05am, Monday, 04'th Apr 2022
BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wit
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call Transcript
05:41pm, Thursday, 17'th Mar 2022
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
11:53am, Thursday, 17'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis
AbbVie, Inc. (NYSE: ABBV) announced
Recap: X4 Pharmaceuticals Q4 Earnings
10:46am, Thursday, 17'th Mar 2022 Benzinga
X4 Pharmaceuticals (NASDAQ: XFOR ) reported its Q4 earnings results on Thursday, March 17, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings X4 Pharmaceuticals missed estimated earnings by 82.35%, reporting … Full story available on Benzinga.com
